J.W. Cole Advisors Inc. raised its position in shares of Edwards Lifesciences Co. (NYSE:EW – Get Rating) by 5.3% in the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 3,364 shares of the medical research company’s stock after purchasing an additional 170 shares during the quarter. J.W. Cole Advisors Inc.’s holdings in Edwards Lifesciences were worth $396,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds also recently modified their holdings of the stock. BlackRock Inc. lifted its position in shares of Edwards Lifesciences by 7.6% during the 4th quarter. BlackRock Inc. now owns 57,040,983 shares of the medical research company’s stock valued at $7,389,659,000 after acquiring an additional 4,007,132 shares during the last quarter. Vanguard Group Inc. lifted its position in shares of Edwards Lifesciences by 1.3% during the 1st quarter. Vanguard Group Inc. now owns 49,724,866 shares of the medical research company’s stock valued at $5,853,612,000 after acquiring an additional 648,217 shares during the last quarter. State Street Corp lifted its position in shares of Edwards Lifesciences by 3.7% during the 4th quarter. State Street Corp now owns 26,920,713 shares of the medical research company’s stock valued at $3,487,578,000 after acquiring an additional 948,638 shares during the last quarter. Capital International Investors lifted its holdings in shares of Edwards Lifesciences by 1.0% in the first quarter. Capital International Investors now owns 22,150,133 shares of the medical research company’s stock valued at $2,607,436,000 after purchasing an additional 218,908 shares in the last quarter. Finally, Alliancebernstein L.P. lifted its holdings in shares of Edwards Lifesciences by 4.6% in the fourth quarter. Alliancebernstein L.P. now owns 13,398,520 shares of the medical research company’s stock valued at $1,735,778,000 after purchasing an additional 583,209 shares in the last quarter. Institutional investors and hedge funds own 81.33% of the company’s stock.
Analyst Upgrades and Downgrades
A number of analysts have recently issued reports on EW shares. Stifel Nicolaus reduced their target price on Edwards Lifesciences from $128.00 to $115.00 in a report on Monday, July 18th. StockNews.com upgraded Edwards Lifesciences from a “hold” rating to a “buy” rating in a report on Wednesday, August 17th. Cowen lowered their target price on shares of Edwards Lifesciences from $140.00 to $125.00 in a research report on Monday, July 11th. Truist Financial lowered their price target on Edwards Lifesciences from $140.00 to $120.00 and set a “buy” rating on the stock in a research report on Wednesday, July 20th. Finally, Morgan Stanley lowered their price target on Edwards Lifesciences from $136.00 to $119.00 and set an “overweight” rating on the stock in a research report on Friday, July 15th. Three research analysts have rated the stock with a hold rating and nineteen have assigned a buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $126.19.
Insiders Place Their Bets
Edwards Lifesciences Price Performance
EW opened at $88.83 on Tuesday. The company has a fifty day moving average price of $98.20 and a two-hundred day moving average price of $102.37. The company has a debt-to-equity ratio of 0.10, a quick ratio of 2.60 and a current ratio of 3.37. Edwards Lifesciences Co. has a 52 week low of $85.58 and a 52 week high of $131.73. The firm has a market capitalization of $55.07 billion, a PE ratio of 38.45, a P/E/G ratio of 2.76 and a beta of 1.14.
Edwards Lifesciences (NYSE:EW – Get Rating) last released its earnings results on Thursday, July 28th. The medical research company reported $0.63 EPS for the quarter, missing analysts’ consensus estimates of $0.64 by ($0.01). Edwards Lifesciences had a return on equity of 24.77% and a net margin of 27.18%. The business had revenue of $1.37 billion for the quarter, compared to analyst estimates of $1.40 billion. During the same period in the prior year, the firm posted $0.64 EPS. Edwards Lifesciences’s revenue was down .2% on a year-over-year basis. As a group, analysts anticipate that Edwards Lifesciences Co. will post 2.51 earnings per share for the current year.
Edwards Lifesciences Company Profile
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases.
- Get a free copy of the StockNews.com research report on Edwards Lifesciences (EW)
- Oracle’s Short-Term Pain Could Be Your Long-Term Gain
- Lucid is Looking Like a Clear EV Winner
- Still Lovin’ It: Investors Keep Visiting McDonald’s
- Did FedEx Just Deliver A Buying Opportunity?
- Autozone Shifts Back Into Rally-Mode, New Highs Are In Sight
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.